CliffBio
biologic

Egrifta WR

tesamorelin

Loss of exclusivityMarch 2037projected — 12-year biologic exclusivity estimate
CompanyTheratechnologies →See this company's full patent-cliff portfolio

Drug detail

Brand nameEgrifta WR
Active ingredienttesamorelin
Strength11.6MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2025
Marketing statusRx

More from Theratechnologies

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Egrifta WR patent cliff — loss of exclusivity March 2037 | CliffBio